Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
German drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
Institut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.
The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
With €600m from a directed share issue in its coffers, BICO finalises the acquisition of QInstruments, a specialist in advanced sample preparation automation.
The European Circular Bioeconomy Fund, initiated by the EU, has raised more than €200m that will be used to drive the transformation towards a bio-based economy.
Gerd Altmann/pixabay.comGerman CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Bad news for Swiss drug discovery company Idorsia: Its Fabry disease hopeful lucerastat failed to reduce neuropathic pain in patients.
Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.